
Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

Mariana Chavez Mac Gregor, MD, MSc, associate professor, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses the use of chemotherapy in patients with node-positive, hormone receptor (HR)-positive, HER2-negative breast cancer.

Published: April 16th 2019 | Updated: